Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress.
Voigt. Annet A; Jelinek. Herbert F HF
Key Findings
- Humanin levels were significantly lower in the impaired fasting glucose group compared to healthy controls (p = 0.0001).
- Humanin is a mitochondrial peptide that can protect cells from oxidative stress and improve insulin sensitivity in animal models.
- The decrease in humanin may reflect an early adaptive response to rising blood glucose and oxidative stress, suggesting it could serve as a biomarker for early metabolic dysfunction.
Practical Outcomes
- For biohackers, this suggests that tracking humanin isn’t yet a practical DIY tool, but strategies that boost mitochondrial health (e.g., regular exercise, NAD+ precursors, or emerging humanin mimetics) might help maintain its protective effects. Until humanin supplements are clinically validated, focus on proven methods to reduce oxidative stress and improve insulin sensitivity.
Summary
The study found that people with slightly high fasting blood sugar (impaired fasting glucose) have lower levels of a tiny protein called humanin in their blood, which may signal early oxidative stress linked to diabetes. Humanin is known to help protect cells from damage and improve insulin sensitivity in animal tests, but this is the first human data showing its levels drop when blood sugar starts to rise.
Abstract
Mitochondrial RNR-2 (mt-RNR2, humanin) has been shown to play a role in protecting several types of cells and tissues from the effects of oxidative stress. Humanin (HN) functions through extracellular and intracellular pathways adjusting mitochondrial oxidative phosphorylation and ATP production. Addition of HN improved insulin sensitivity in animal models of diabetes mellitus but no clinical studies have been carried out to measure HN levels in humans associated with hyperglycemia. The plasma levels of HN in participants attending a diabetes complications screening clinic were measured. Clinical history and anthropometric data were obtained from all participants. Plasma levels of HN were measured by a commercial ELISA kit. All data were analyzed applying nonparametric statistics and general linear modeling to correct for age and gender. A significant decrease (P = 0.0001) in HN was observed in the impaired fasting glucose (IFG) group (n = 23; 204.84 ± 92.87 pg mL(-1)) compared to control (n = 58; 124.3 ± 83.91 pg mL(-1)) consistent with an adaptive cellular response by HN to a slight increase in BGL.
Study Information
pubmed
2016
2016-05-01T00:00:00.000Z
10.14814/phy2.12796
43
25